Revvity has acquired Human Cell Design for an undisclosed amount. The transaction brings the cell model specialist fully under Revvity’s ownership, expanding the latter’s portfolio in early-stage drug discovery and development tools.
Human Cell Design assists industrial and academic groups by providing unique physiologically relevant human cell models. Its offerings are designed to help researchers deliver better therapies to patients faster, with a focus on replicating human biology more accurately than standard cell lines. Revvity, a broader life sciences and diagnostics company, supplies instruments, reagents, and services used across research and clinical workflows.
The acquisition is strategic for Revvity because it adds differentiated biological models to its existing assay and detection platforms. Human Cell Design’s expertise in creating complex, human-relevant systems can complement Revvity’s screening technologies, potentially allowing customers to validate drug candidates earlier with more predictive data. For Human Cell Design, joining Revvity provides access to a larger commercial infrastructure and a global customer base, which may accelerate the adoption of its models beyond current niche applications.
The deal is expected to strengthen Revvity’s position in the growing market for advanced cell models, where pharmaceutical and biotech firms increasingly seek alternatives to traditional animal testing. By integrating Human Cell Design’s capabilities, Revvity can offer a more seamless workflow from target validation to lead optimization. No financial terms were disclosed, and the completion of the acquisition has been confirmed by both parties.
The combined entity will focus on broadening the availability of these cell models across therapeutic areas, with an emphasis on integrating them into Revvity’s existing service and software offerings. Over the coming quarters, the integration will likely center on aligning product roadmaps and ensuring that existing Human Cell Design clients experience continuity while gaining access to Revvity’s broader toolkit.